| 1 |
Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000 [J]. N Engl J Med, 2003, 348(16): 1546-1554.
|
| 2 |
Coopersmith CM, Wunsch H, Fink MP, et al. A comparison of critical care research funding and the financial burden of critical illness in the United States [J]. Crit Care Med, 2012, 40(4): 1072-1079.
|
| 3 |
Cheng B, Xie G, Yao S, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China [J]. Crit Care Med, 2007, 35(11): 2538-2546.
|
| 4 |
Yang WS, Park YC, Kim JH, et al. Nanostructured, self-assembling peptide K5 blocks TNF-alpha and PGE(2) production by suppression of the AP-1/p38 pathway [J]. Mediators Inflamm, 2012, 2012: 489810.
|
| 5 |
Byeon SE, Lee J, Yoo BC, et al. p38-targeted inhibition of interleukin-12 expression by ethanol extract from Cordyceps bassiana in lipopolysaccharide-activated macrophages [J]. Immunopharmacol Immunotoxicol, 2011, 33(1): 90-96.
|
| 6 |
Garcia J, Lemercier B, Roman-Roman S, et al. A Mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways [J]. J Biol Chem, 1998, 273(51): 34391-34398.
|
| 7 |
Amirouche A, Tadesse H, Lunde JA, et al. Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics [J]. Hum Mol Genet, 2013, 22(15): 3093-3111.
|
| 8 |
Pietersma A, Tilly BC, Gaestel M, et al. p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level [J]. Biochem Biophys Res Commun, 1997, 230(1): 44-48.
|
| 9 |
Ren F, Zhang HY, Piao ZF, et al. Inhibition of glycogen synthase kinase 3b activity regulates Toll-like receptor 4-mediated liver inflammation [J]. Zhonghua gan zang bing za zhi, 2012, 20(9): 693-697.
|
| 10 |
Lim AK, Tesch GH. Inflammation in diabetic nephropathy [J]. Mediators Inflamm, 2012, 2012: 146154.
|
| 11 |
Ko HM, Joo SH, Kim P, et al. Effects of Korean Red Ginseng extract on tissue plasminogen activator and plasminogen activator inhibitor-1 expression in cultured rat primary astrocytes [J]. J Ginseng Res, 2013, 37(4): 401-412.
|
| 12 |
Guma M, Hammaker D, Topolewski K, et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6 [J]. Arthritis Rheum, 2012, 64(9): 2887-2895.
|
| 13 |
Jackson JR, Bolognese B, Hillegass L, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models [J]. J Pharmacol Exp Ther, 1998, 284(2): 687-692.
|
| 14 |
Brando Lima AC, Machado AL, Simon P, et al. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation [J]. Pharmacol Rep, 2011, 63(4): 1029-1039.
|
| 15 |
Menghini R, Casagrande V, Menini S, et al. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice [J]. Diabetes, 2012, 61(2): 454-462.
|
| 16 |
Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors [J]. Genes Cancer, 2013, 4(9-10): 342-359.
|
| 17 |
Huang X, Zeng Y, Jiang Y, et al. Lipopolysaccharide-Binding Protein Downregulates Fractalkine through Activation of p38 MAPK and NF-kappaB [J]. Mediators Inflamm, 2017, 2017: 9734837.
|
| 18 |
Ghosh S, Hayden MS. Celebrating 25 years of NF-kappaB research [J]. Immunol Rev, 2012, 246(1): 5-13.
|
| 19 |
Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation [J]. Nat rev Immunol, 2008, 8(11): 837-848.
|
| 20 |
Arnalich F, Garcia-Palomero E, López J, et al. Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis [J]. Infect Immun, 2000, 68(4): 1942-1945.
|
| 21 |
Gustin JA, Ozes ON, Akca H, et al. Cell Type-specific expression of the IκB kinases determines the significance of phosphatidylinositol 3-Kinase/Akt signaling to NF-κB activation [J]. J Biol Chem, 2004, 279(3): 1615-1620.
|
| 22 |
Zhang X, Li N, Shao H, et al. Methane limit LPS-induced NF-kappaB/MAPKs signal in macrophages and suppress immune response in mice by enhancing PI3K/AKT/GSK-3beta-mediated IL-10 expression [J]. Sci Rep, 2016, 6: 29359.
|
| 23 |
Rehani K, Scott DA, Renaud D, et al. Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells [J]. Biochim Biophys Acta, 2008, 1783(3): 375-382.
|
| 24 |
Williams DL, Ozment-Skelton T, Li C. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury [J]. Shock, 2006, 25(5): 432-439.
|
| 25 |
Andrejko KM, Raj NR, Kim PK, et al. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters [J]. Shock, 2008, 29(4): 490-496.
|
| 26 |
Hui L, Yao Y, Wang S, et al. Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality [J]. J Trauma, 2009, 66(3): 859-865.
|
| 27 |
Kim JH, Kim SJ, Lee IS, et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway [J]. J Immuno, 2009, 182(4): 2458-2466.
|
| 28 |
Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation [J]. Immunity, 2011, 34(2): 213-223.
|
| 29 |
Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs [J]. JAKSTAT, 2013, 2(1): e23820.
|
| 30 |
Majumder S, Zhou LZ, Chaturvedi P, et al. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha [J]. J Immunol, 1998, 161(9): 4736-4744.
|
| 31 |
Kim MO, Suh HS, Brosnan CF, et al. Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta [J]. J neurochem, 2004, 90(2): 297-308.
|
| 32 |
Agarwal D, Dange RB, Raizada MK, et al. Angiotensin II causes imbalance between pro- and anti-inflammatory cytokines by modulating GSK-3beta in neuronal culture [J]. Br J Pharmacol, 2013, 169(4): 860-874.
|
| 33 |
Pavlov VA, Parrish WR, Rosas-Ballina M, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway [J]. Brain Behav Immun, 2009, 23(1): 41-45.
|
| 34 |
Pontet J, Contreras P, Curbelo A, et al. Heart rate variability as early marker of multiple organ dysfunction syndrome in septic patients [J]. J Crit Care, 2003, 18(3): 156-163.
|
| 35 |
van Westerloo DJ, Giebelen IA, Florquin S, et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis [J]. J Infect Dis, 2005, 191(12): 2138-2148.
|
| 36 |
Kessler W, Traeger T, Westerholt A, et al. The vagal nerve as a link between the nervous and immune system in the instance of polymicrobial sepsis [J]. Langenbecks Arch Surg, 2006, 391(2): 83-87.
|
| 37 |
Hofer S, Eisenbach C, Lukic IK, et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis [J]. Crit Care Med, 2008, 36(2): 404-408.
|
| 38 |
Fodale V, Santamaria LB. Cholinesterase inhibitors improve survival in experimental sepsis: a new way to activate the cholinergic anti-inflammatory pathway [J]. Crit Care Med, 2008, 36(2): 622-623.
|